Literature DB >> 8192455

Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.

J Brajtburg1, S Elberg, S J Travis, G S Kobayashi.   

Abstract

Amphotericin B (AmB) with deoxycholate (Fungizone) and AmB incorporated into mixed micelles (AmB-mixMs) composed of egg lecithin with glycocholate, deoxycholate, or taurocholate were compared as treatments for murine infections. For mice infected with Candida albicans, treatment consisted of a single intravenous injection; for mice infected with Cryptococcus neoformans, treatment consisted of two intravenous injections. The maximal tolerated doses of AmB as Fungizone were 1.25 mg/kg of body weight in mice with candidiasis and 2.5 mg/kg of body weight in mice with cryptococcosis. The AmB-mixMs were nontoxic to mice at doses of 80 and 100 mg/kg of body weight and were therapeutically more active than the maximal tolerated dose of Fungizone in both models of infection. However, when Fungizone or AmB-mixMs were administered at equivalent doses of AmB, AmB-mixMs were more active in treating murine candidiasis, whereas Fungizone was more active in treating murine cryptococcosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8192455      PMCID: PMC284443          DOI: 10.1128/AAC.38.2.294

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.

Authors:  E D Ralph; A M Khazindar; K R Barber; C W Grant
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

2.  Cardiopulmonary toxicity after liposomal amphotericin B infusion.

Authors:  S J Levine; T J Walsh; A Martinez; P Q Eichacker; G Lopez-Berestein; C Natanson
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

3.  Liposomes prepared dynamically by interactions between bile salt and phospholipid molecules.

Authors:  K Son; H Alkan
Journal:  Biochim Biophys Acta       Date:  1989-06-06

4.  Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice.

Authors:  C Tremblay; M Barza; C Fiore; F Szoka
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

5.  Inhibition of amphotericin B (Fungizone) toxicity to cells by egg lecithin-glycocholic acid mixed micelles.

Authors:  J Brajtburg; S Elberg; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

6.  In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B.

Authors:  R L Hopfer; K Mills; R Mehta; G Lopez-Berestein; V Fainstein; R L Juliano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.

Authors:  R Kirsh; R Goldstein; J Tarloff; D Parris; J Hook; N Hanna; P Bugelski; G Poste
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

8.  Solubility and stability of amphotericin B in human serum.

Authors:  L C Edmonds; L Davidson; J S Bertino
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

9.  Amphotericin B revisited: reassessment of toxicity.

Authors:  J S Clements; J E Peacock
Journal:  Am J Med       Date:  1990-05       Impact factor: 4.965

10.  Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice.

Authors:  J A Gondal; R P Swartz; A Rahman
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more
  5 in total

Review 1.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

2.  A novel injectable water-soluble amphotericin B-arabinogalactan conjugate.

Authors:  R Falk; A J Domb; I Polacheck
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses.

Authors:  J Brajtburg; S Elberg; G S Kobayashi; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

4.  Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans.

Authors:  M A Hossain; S Maesaki; H Kakeya; T Noda; K Yanagihara; E Sasaki; Y Hirakata; K Tomono; T Tashiro; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

5.  Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral Candida albicans.

Authors:  Li Zhou; Peipei Zhang; Zhuo Chen; Shaona Cai; Ting Jing; Huihui Fan; Fei Mo; Jiye Zhang; Rong Lin
Journal:  Int J Nanomedicine       Date:  2017-06-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.